INTRODUCTION

50
The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) causes 51 severe pneumonia and renal failure in infected patients and has led to 206 laboratory-confirmed 52 MERS cases, including 86 deaths (a case fatality rate of ~42%) (1) 
89
In this study, we report the generation of a novel monoclonal antibody, Mermab1, which 
MATERIALS AND METHODS
96
Ethics Statement. Female BALB/c mice at the age of 6-8 weeks old were used for mAb protein fragments (strain EMC, GenBank ID: AFS88936.1) were expressed and purified using a 106 protocol as previously described (31). Briefly, the protein fragments were fused with either a 107 C-terminal Fc tag of human IgG or a C-terminal His 6 tag, and were transiently expressed in 293T 108 cells. The protein fragments were harvested from the cell culture supernatants, and purified using 
111
Recombinant human DPP4 ectodomain (residues 39-766) was expressed and purified using a hybridomas were screened by ELISA using a recombinant MERS-CoV S1 containing an C-terminal His 6 tag (S1-His) (32). Positive cells were expanded and subcloned to generate stable 125 hybridoma cell lines. The mAbs were purified from ascites using Protein A and G Sepharose 4
126
Fast Flow (GE Healthcare). To obtain the Fab region of mAbs, mAbs were digested using papain 127 (Sigma, MO) and the resulting Fabs were purified as previously described (24). Anti-SARS-CoV-RBD mAb, 33G4, was used as a control (27). For neutralizing assay using
150
Calu-3 cells, the mixture of Mersmab1 and virus was incubated with Calu-3 cells at 37°C for 24 h.
151
The efficacy of Mersmab1 in attenuating MERS-CoV-induced CPE was observed under an were then added to the mixture. After incubation at room temperature for 1 h, the AlphaScreen 160 signal was detected using an EnSpire plate reader (PerkinElmer).
161
The AlphaScreen assay was also used to detect whether Mersmab1 inhibited the binding anti-mouse IgG (1:3,000, GE Healthcare), IgG1 (1:2,000), IgG2a (1:5,000), IgG2b (1:2,000) and 180 IgG3 (1:2,000) (Invitrogen, CA). After incubation for another hour at 37°C, the substrate 
184
To detect the binding between Mersmab1 and denatured MERS-CoV spike protein fragments,
185
ELISA plates were coated with recombinant spike protein fragments (1 µg/ml) at 4°C overnight,
186
and then treated with Dithiothreitol (DTT, 10 mM, Sigma) at 37°C for 1 h, followed by addition
187
of Iodoacetamide (50 mM, Sigma) at 37°C for 1 h to stop the reaction (24). After three washes,
188
regular ELISA was performed as described above. 
RESULTS
191
Generation of Mersmab1 that potently neutralizes MERS-CoV cell entry
192
To generate mAbs capable of neutralizing MERS-CoV infection, mice were immunized with 193 recombinant MERS-CoV S1 fused to a C-terminal Fc tag (S1-Fc). Subsequently, stable hybridoma 194 cell lines were generated for screening of positive clones using ELISA. These selected clones not 195 only reacted to recombinant MERS-CoV S1-Fc protein, but also to recombinant MERS-CoV S1 (Fig. 1A, 1B , and 1C) (27).
210
Accordingly, Mersmab1 was chosen for further characterization and evaluation. and DPP4-expressing Huh-7 cells was blocked by Mersmab1 (Fig. 2B) , and that the blockade was 222 also in a dose-dependent manner (Fig. 2C) . In contrast, the anti-SARS-CoV mAb 33G4 was between MERS-CoV RBD and Mersmab1 using both AlphaScreen assay and ELISA.
228
AlphaScreen assay showed that Mersmab1 specifically bound to MERS-CoV RBD, but not to 229 SARS-CoV RBD (Fig. 3A) . ELISA demonstrated that Mersmab1 specifically bound to
230
MERS-CoV S1-Fc and RBD-Fc, but not to MERS-CoV S1 N-terminal domain (S-NTD-Fc),
231
S2-Fc, or hFc (Fig. 3B) . As a control, anti-SARS-CoV mAb 33G4 only bound to SARS-CoV
232
RBD, but not to any of the MERS-CoV spike protein fragments (Fig. 3A and 3B ). ELISA also 233 uncovered that the antibody subtype of Mersmab1 was mainly IgG1 (Fig. 3C) . ELISA further 
249
E536 and E565, which do not directly contact DPP4, were also mutated to alanines as controls.
250
Each of the mutant RBD-Fc proteins containing one of the aforementioned mutations was 251 expressed and purified without significant change in its expression levels or solubility (Fig. 4A) .
252
This observation indicates that none of these mutations affected the native structure of the RBD,
253
which is consistent with the fact that all of these selected residues are located on the protein 254 surface and not involved in protein folding. ELISA showed that a number of these RBD mutations,
255
including L506A, D510A, R511A, E513A, and W553A, led to significant loss of binding affinity Mersmab1 at all; neither did the two control mutations, E536A and E565A (Fig. 4B) . Pseudovirus (Fig. 5A ), which overlaps with the 268 DPP4-binding region in MERS-CoV RBD (Fig. 5B) . Therefore, the neutralization mechanism of
269
Mersmab1 is based on the competitive blocking of MERS-CoV RBD binding to DPP4.
270
Interestingly, these recognizing epitopes appear to differ from the recognizing epitopes of 
